CCCC - C4 Therapeutics Inc
IEX Last Trade
6.32
-0.110 -1.741%
Share volume: 784,021
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$6.43
-0.11
-1.71%
Fundamental analysis
9%
Profitability
0%
Dept financing
9%
Liquidity
75%
Performance
2%
Performance
5 Days
-4.82%
1 Month
0.32%
3 Months
26.91%
6 Months
-42.28%
1 Year
115.70%
2 Year
-38.16%
Key data
Stock price
$6.32
DAY RANGE
N/A - N/A
52 WEEK RANGE
$1.06 - $11.88
52 WEEK CHANGE
$1.19
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/30/2024
Company detail
CEO:
Region: US
Website: c4thera.com
Employees: 152
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: c4thera.com
Employees: 152
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
c4 therapeutics is an early stage drug discovery company whose mission is to harness targeted protein degradation to develop therapeutics for a broad range of diseases. the centerpiece of our approach is the degronimid® platform, which enables highly selective small molecule binders to target disease causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system.
Recent news